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Available online 14 September 2016Despite considerable research efforts, the ﬁnding of reliable tumor biomarkers remains challenging and unre-
solved. In recent years a novel diagnostic biomedical tool with high potential has been identiﬁed in extracellular
nanovesicles or exosomes. They are released by themajority of the cells and contain detailedmolecular informa-
tion on the cell of origin including tumor hallmarks. Exosomes can be isolated from easy accessible body ﬂuids,
andmost importantly, they can provide several biomarkers, with different levels of speciﬁcity. Recent clinical ev-
idence shows that the levels of exosomes released into body ﬂuids may themselves represent a predictive/diag-
nostic of tumors, discriminating cancer patients fromhealthy subjects. The aim of this review is to highlight these
latest challenging ﬁndings to provide novel and groundbreaking ideas for successful tumor early diagnosis and
follow-up.
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Research performed over recent years has demonstrated that body
ﬂuids contain substantial amounts of extracellular vesicles (EV) with
sizes ranging between 30 and 1000 nm, which are surrounded by phos-
pholipid membranes characterized by different micro-domains such as
lipid-rafts and caveolae. Two main types of EVs have been described,
nanosized exosomes (30–150 nm), that are derivatives of the
endosomal system, and microvesicles (100–1000 nm) that are pro-
duced by outward budding of the plasma membrane (Yáñez-Mó et al.,
2015).
Exosomes are released by most cell types and mediate targeted in-
tercellular communication under physiological and pathophysiological
conditions, including different types of cancer (Ludwig and Giebel,
2012). Fig. 1 shows representative TEM pictures of epon embedded
samples of human lung mucoepidermoid cells and EVs isolated from
the same cells. The variety in size of intracellular vesicles contained
within multivesicular bodies is clear and the same variety is present
on EVs puriﬁcation while the ultracentrifugation repeated rounds re-
duce the vesicle diameter to a range in which exosomes are enclosed.
However, also other ultrastructural parameters may help in
distinguishing exosomes from the other EVs, such as the typical bilayer
membrane structure (Fig. 1 B and C).Since EVs contain cell-type speciﬁc signatures, they have been pro-
posed as biomarkers in a variety of diseases (Colombo et al., 2012;
Gamez-Valero et al., 2015). They are composed by speciﬁc sets of mole-
cules including proteins, lipids, metabolites and nucleic acids that alto-
gether reﬂect the source cell (Lo Cicero et al., 2015; Chevillet et al.,
2014). According to their molecular signature they can reach selected
target cells at local or distance sites, within or between organs
(Cantaluppi et al., 2012; Quesenberry et al., 2015; Hoshino et al.,
2015). Giving their features, EVs provide ideal candidates as potentially
the most reliable biomarkers in medicine (Fais et al., 2016). The major-
ity of the available clinical data supporting the use of EVs as a source of
disease biomarkers have been obtained from studies in cohort of cancer
patients. This, of course,might be of paramount importance for the clin-
ical management of tumor patients, but probably for ensemble of the
human diseases, being, unfortunately, the identiﬁcation of speciﬁc dis-
ease biomarkers an unmet clinical need. However, the scientiﬁc com-
munity is producing a huge effort in trying to discover new EVs-
related disease biomarkers (Fais et al., 2016), possibly useful as speciﬁc
targets for new therapeutic approaches as well (Lener et al., 2015).
2. The Weakness of Existing Tumor Biomarkers and the Promising
Role of Plasmatic Exosomes
Currently the diagnosis and the follow-up of cancer patients suffer
the absence of speciﬁc markers. In fact, clinical oncologists very often
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Fig. 1. Representative TEM images of epon-embedded and sectioned exosomes from cell
cultures (NCI-H292 cells, human lung mucoepidermoid cells) supernatant.
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non-speciﬁc markers to have a comprehensive general sight on the
health status patient-by-patient. Plasmatic levels of existing tumor
markersmay change accordinglywith the disease status, the side effects
of current therapies and the co-existence of clinical complications.
Moreover, too often tumor biomarkers may increase in other disease
conditions with very low level of speciﬁcity, which does not allowreliable screening test and too often leads to mis- or overdiagnosis. A
clear example is one themost used tumor biomarkers, the prostatic spe-
ciﬁc antigen (PSA), which exploited worldwide as a prostate cancer
(PCA)marker. In fact, serum PSA quantiﬁcation is used in PCA screening
from a couple of decades, with the idea to rapidly replace the digital rec-
tal examination for early detection of prostate cancer (Catalona et al.,
1991; Schröder, 2009; Brawley, 2012). Nevertheless, this diagnostic
method is quite controversial (Andriole, 2009; Hoffman, 2011;
Sturgeon et al., 2008) due to the likelihood of false positives, including
benign prostatic hyperplasia (BPH) (Hoffman, 2011). Since PSA testing
fails to discriminate between BPH and tumors, over-diagnosis and
over-treatment are frequently a problem, increasing patient suffering
due to the well known side effects of the few therapeutic options
(Etzioni and Feuer, 2008; Schröder, 2009; Hoffman, 2011; Vickers et
al., 2014). PSA values above 4.0 ng per milliliter are considered abnor-
mal, however, cut-off levels can change with age, race and individual
physiological conditions (Etzioni and Feuer, 2008; Schröder, 2009;
Hoffman, 2011), and no signiﬁcant progress has been achieved in the
last decades (Steuber et al., 2008). Interestingly, some preliminary clin-
ical studies have shown that PSA is detectable in preparations of plasma
and urine-derived EVs (Mitchell et al., 2009; Mizutani et al., 2014). This
suggests that studies aimed at quantiﬁcation and characterization of
PSA-associated plasmatic and urine nanovesicles may be extremely
helpful in distinguishing between cancer and benign tumors, thus
allowing screening test in extended males populations. This should be
also true for all the existing clinical biomarkers of tumors, that in fact
are not speciﬁc. Currently, available biomarkers for cancer screening
and diagnosis regularly display a low level of speciﬁcity, while showing
some sensitivity, not discriminating patients at early stages of disease
(false negatives), or detecting those with no disease (false positives).
Tumor-derived EVs are proposed to contain tumor-speciﬁc molecular
signatures, qualifying them as potential biomarkers in tumor diagnos-
tics (Zocco et al., 2014). EVs can be puriﬁed using sequential ultracentri-
fugation rounds from almost all body ﬂuids, including blood and urine.
As recently reported, the clinical evidence on the relevance of EVs as dis-
ease biomarkers is rapidly increasing (Fais et al., 2016). In fact, due to
their complex assembly, exosomes may offer the potential of being
more sensitive and speciﬁc than currently available clinical biomarkers
(Mitchell et al., 2009). Real clinical studies are scarce, the majority de-
scribing the detection of novel markers in exosome preparations, but
only few of them focus on the clinical relevance of the discovery. There-
fore it is difﬁcult to have a clear view on the issue, and the clinical data
are so scattered that it is virtually impossible to propose them but with
rambling summaries of the single reports. The result is that there are not
yet clinical studies with a reliable evidence that plasmatic EVs bear
markers of a disease, or, in the case of tumors, markers able of clear dis-
crimination between different tumor histologies. It is out of the purpose
of this review to summarize them, so here we just suggest the readers
some recent position papers on this topic (Iero et al., 2008; Properzi et
al., 2013; Properzi et al., 2013; Zocco et al., 2014; Fais et al., 2016).
Nevertheless, although a number of studies suggest that exosomes
may contain speciﬁc markers useful for tumor early diagnosis and fol-
low-up, these markers are still a sort of Holy Grail for cancerologists.
Our hypothesis is that, “rather than to the ﬁnger one should look to
the sky”: tumor patients have higher plasmatic exosome levels as com-
pared to the controls. The ensemble of the clinical data on EVs levels in
various body ﬂuids of tumor patients to date does not support the exis-
tence of clear and speciﬁc biomarkers. However, some pre-clinical data
actually suggest that exosomes may represent a preferential vehicle for
biomarkers released by tumors. In this context, a translational study
provided evidence of feasible human body ﬂuids EVs quantiﬁcation by
an immunocapture-base ELISA test (Logozzi et al., 2009). This assay
has shown that circulating exosome levels may reﬂect the tumor
mass, using a surrogate tumor marker, such as caveolin, or simply a
housekeeping exosome marker such as CD63; using both parameters
tumor patients showed higher EVs marker as compared to healthy
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plasmatic exosome levels to the tumor size are shown (Logozzi et al.,
2009). Some pre-clinical data suggest that the tumor microenviron-
mental conditions, such us extracellular acidity, may trigger an in-
creased exosome release, that is inhibited through the use of various
anti-acidic approaches, including both buffers and proton pump inhibi-
tors (Parolini et al., 2009; Federici et al. 2014). In particular, tumor acid-
ity is related to an increased tumor exosomes plasmatic levels (Federici
et al. 2014). This suggests that themicroenvironmental conditions, that
are not present in the same tissues in both healthy or benign tumor con-
dition, may favour the presence of tumor markers on exosomes, for in-
stance of some enzymes such as PSA, needing an acidic
microenvironment for a full activation. This may be the case of survivin
as well, whose presence on plasmatic exosomes of prostate cancer pa-
tients has been proposed as an early detectionmarker of prostate cancer
(Khan et al., 2012).
3. Are Plasmatic Exosome Levels aMarker of Tumor Progression and
Recurrence?
The ﬁrst evidence supporting the notion that EVs levels in human
body ﬂuids may represent potential markers for tumor progression
was provided by a clinical study exploiting an immunocapture-based
assay (Logozzi et al., 2009). The study showed that a considerable
amount of melanoma patients with advanced disease presented signif-
icant higher level of plasmatic exosomes as compared to healthy volun-
teers. More in particular, stage III and IV melanoma patients showed
increased levels of plasmatic caveolin-1 and CD63-positive EVs
(Logozzi et al., 2009). EV-associated caveolin-1 displayed a sensitivity
of 69% and speciﬁcity of 96.3%, while a conventional cancer biomarker
used in the follow-up ofmelanomapatients, such as Lactate dehydroge-
nase (LDH) serum levels, was altered in only 12.5% of patients (Logozzi
et al., 2009). These ﬁndings have received support by a recent study
showing that in melanoma patients MIA and S100B positive exosomes
were signiﬁcantly higher than in healthy controls (Alegre et al., 2016).
This hypothesis has been further suggested by another recent paper
(Caivano et al., 2015), showing by FACS analysis that the amount of
exosomes isolated from the serumof patientswith different types of he-
matological tumours was signiﬁcantly higher than in healthy subjects.
Interestingly, they identiﬁed markers on circulating nanovesicles
reﬂecting their cellular source, such as CD19 in B cell neoplasm, CD38
in multiple myeloma, CD13 in myeloid tumors and CD30 in Hodgkin's
lymphoma (Caivano et al., 2015). According to these ﬁndings, a recent
study has shown that in PCA patient nanovesicles levels are increased
in body ﬂuids, when measured by a time-resolved ﬂuorescence immu-
noassay, capturing CD9 and CD63 positive exosomes (Duijvesz et al.,
2015). A clinical study performed in patientswith colorectal cancer sup-
ported these evidences obtained in other tumor histologies (Silva et al.,
2012). The levels of plasmatic nanovesicles were quantiﬁed in 91 colo-
rectal cancer patients and the results showed that theywere statistically
higher than in healthy controls. Moreover, exosome levels correlated
with high levels of serum carcino-embryonic antigen (CEA). Further
analysis showed that exosome levels signiﬁcantly correlated with
both, lower level of tumor differentiation and shorter overall survival
(Silva et al., 2012). In prostate cancer patients the EV concentration, as
measured by nanoparticle tracking analysis (NTA), was proven higher
than in the plasma of healthy controls (Nawaz et al., 2014). Recently, a
milestone study has shown that glypican-1 (GPC1) positive exosomes
were detectable in the serum of patients with pancreatic cancer with
high level of speciﬁcity and sensitivity, and could distinguish healthy
subjects and patients with a benign pancreatic disease from patients
with early- and late-stage pancreatic cancer (Melo et al., 2015). Howev-
er, the same study showed that high levels of GPC1 on nanosized EVs
were also detected in breast cancer patients, suggesting that an increase
of circulating EV might represent a sign of the presence of a malignant
cancers, suitable to be used in the clinical follow-up of cancer patients.Thismay represent a valuable tool in cancer screening and in the assess-
ment of the clinical status, as well.
Interesting data suggest that the levels of circulating EVsmay be also
exploited in assessing the effectiveness of a therapy in cancer patients.
For instance, the effect of the treatment with Imatinib for gastrointesti-
nal stromal tumor was monitored, showing that the concentration of
EVs before the treatment was increased with respect to control
(Ogorevc et al., 2013). Furthermore, in a preclinical setting, treatment
with proton pump inhibitors in xenograft with human melanoma has
shown that EVs plasmatic levels are consistent with reduction of the
tumor size (Federici et al., 2014).
An interesting study has been very recently published, showing an
increase in EVs release from irradiated compared to non-irradiated
tumor cells (Mutschelknaus et al., 2016). The authors also show an en-
hanced uptake of Evs from both irradiated and non-irradiated cells by
irradiated recipient cells compared to non-irradiated recipient cells, in-
creasing survival. These results demonstrate that radiation inﬂuences
both the abundance and action of exosomes on recipient cells and that
exosomes transmit pro-survival effects by promoting the proliferation
and radioresistance of head and neck cancer cells (Mutschelknaus et
al., 2016). Circulating EVs have been included in the novel concept of
“Liquid Biopsies”. This is a signiﬁcant acknowledgment to clinical results
supporting the hypothesis that plasmatic levels of EVs may represent a
valuable tumor marker (Logozzi et al., 2009; Silva et al., 2012; Alegre et
al., 2016; Caivano et al., 2015; Duijvesz et al., 2015; Melo et al., 2015),
and also to preclinical data showing that exosome levels correlate
with the tumor mass (Logozzi et al., 2009). It is also suggested that
the amount of circulating EVs may represent a new category, that we
want here call for the ﬁrst time “Liquid Tumor Mass”. This notion
needs further support from a larger number of clinical studies, correlat-
ing the circulating exosome levels to the whole tumor mass bymean of
routinediagnostic examinations, includingCT Scan,MNR and PET. How-
ever, “Liquid TumorMass” (LTM)wants also to include the concept that
circulating EVsmay actively contribute to themetastatic tumor dissem-
ination, not only in preparing a sort of niche for the better seeding of cir-
culating tumor cells into the target organs (Peinado et al. 2012), but also
transforming local stem cells in a tumor-like manner (Lugini et al.
2016). Importantly, a general agreement on the method/s to quantify
circulating EVs is required. Indeed, in all the studies reported in this re-
view the EVs levels were quantiﬁed using quite distinct methodologies:
immunocapture-based ELISA, NanoSight-based technologies, ﬂow cy-
tometry, and simple protein counts in the EVs puriﬁcation. It is note-
worthy that all the studies got to the same evidence: tumor patients
have higher circulating EVs levels than healthy individuals. However,
if we want to transfer this approach into the clinical practice we need
an agreement on the most reliable, and probably cheap, methodology
to be used in clinical cancer laboratories worldwide.
Another signiﬁcant issue is that the assessment of EVs levels in can-
cer patients may be improved if implemented with highly speciﬁc
markers. To this purpose, it is mandatory to go ahead with studies
looking at new EVs-related molecules, including proteins, lipids and
nucleic acids. However, this approach should start from the evaluation
of the speciﬁc expression of known tumor markers on EVs. This can
well include some scattered observations obtained in few patients,
such as that of CEA in colon cancer patients (Huber et al., 2005), but
also include many other reports covering virtually all the standard
tumor markers exploited in the clinical management of cancer patients
(reviewed in Zocco et al., 2014).
Some potential biomarkers are currently under investigation, in-
cluding survivin, which has been identiﬁed as a promising surrogate
biomarker for early diagnosis of prostate cancer (Khan et al., 2012). El-
evated levels of EV-expressing TYRP-2, VLA-4, HSP70 and HSP90 have
been also detected in the plasma of melanoma patients (Peinado et al.,
2012). A group of chaperonins, including HSP70 andHSP90, that belong
to the family of heat shock proteins (HSPs), has been recently investi-
gated in order to understand their potential role in cancer pathogenesis
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matically decreased in colon cancer patients after surgically removing
the tumor (Campanella et al., 2015). This suggests that one of the
most interesting exploitation of circulating EVs quantiﬁcation is the fol-
low-up of surgical treatment of cancers, both at the diagnosis and fol-
lowing relapses. Remarkable results were obtained by comparing N-
glycan proﬁles of EVs from indolent and aggressive prostate cancer to
non-cancer conditions (Nyalwidhe et al., 2013). A series of clinical
data of paramount importance for biomarker discovery in body ﬂuids
is summarized in Table 1.
In addition to plasma, urine is another body ﬂuid that can be easily
exploited in the clinical management of cancer patients, particularly in
patients with genitourinary tract malignancies. Interestingly, proteomic
analysis of urinary EVs mirrors reliably certain kidney pathologies as
demonstrated by Pocsfalvi (Pocsfalvi et al., 2015). The authors showed
that polycystin-1 and polycystin-2 expression, together with that of
other Ca2+-binding proteins (annexin A1, annexin A2, protein S100-
A9, protein S100-A8, and retinoic acid induced protein 3) are signiﬁ-
cantly altered.
Altogether the available data suggest that quantiﬁcation and charac-
terization of EVs in human body ﬂuid may be highly helpful as a new
non-invasive diagnostic tool for the clinical management of cancer pa-
tients. We suggest that quantiﬁcation EVs circulating mass may repre-
sent a very important endpoint to be achieved.
4. Conclusions
Currently available tumor biomarkers are an inefﬁcient and unreli-
able tool for both tumor screening and the clinical follow-up of tumor
patients. While the achievement of valuable non-invasive approach
for both diagnosis and prognosis of cancer is a critical and strategic end-
point in the ﬁght against cancer, the results obtained to date are delu-
sive actually. In the last decades a huge amount of data supporting the
importance of extracellularly released vesicles in both physiology and
pathology has been produced. In particular, a deal of studies has
shown that EVs are a natural shuttle for proteins, lipids and nucleic
acid (includingmRNA andmiRNA). This certainly represents an impres-
sive amount of precious information that increases our knowledge on
life science, but also provides a novel idea for improving early diagnosis
of diseases, speciﬁcally of cancer. Cancer and deaths for cancer incidence
were remarkably increasing in the last decades (up to 14.1 million new
cancer cases and 8.2million deaths occurred in 2012worldwide) (Torre
et al., 2015). In the absence of a sufﬁciently effective therapy other than
surgery after an early diagnosis (so called “Secondary Prevention”), it is
particularly urgent to obtain an efﬁcient, non-invasive, and possibly af-
fordable, new diagnostic tools for cancer. This review proposes the de-
termination of human body ﬂuids EVs levels as the most reliable
prognostic and diagnostic tools for both screening and early diagnosis
of cancer and cancer recurrence. The real challenge of this perspective
review is to address the quantiﬁcation of the whole circulating EVsTable 1
Summary of important data showing the utility of exosomes in clinical studies.
Cancer type Marker(s) Bod
Hematological tumors CD9, CD13, CD19, CD30, CD38, CD63 Seru
Prostate cancer CD9, CD63 Urin
Prostate cancer Survivin Plas
Prostate cancer – Plas
Prostate cancer N-linked glycans Pros
Colon cancer Hsp60 Plas
Colon-rectal cancer – Plas
Melanoma CD63, caveolin-1 Plas
Melanoma MIA, S100B Seru
Melanoma TYRP-2, VLA-4, HSP70, HSP90 Plas
Pancreatic cancer Glypican 1 Seru
Brest cancer miR34a, dicer Plas
Gastrointestinal stromal tumor – Plasmass as a way to distinguish between patients with cancer and healthy
individuals. We here emphasize that presently the EVs related markers
did not show cancer type speciﬁcity, but they help in quantifying circu-
lating EVs. In our opinion, the measurement of exosome levels in body
ﬂuids of patients can be an easy and cheap way to reach the same
goal, i.e. early cancer diagnosis and/or follow-up.
The importance of this approach has been recently emphasized in an
article commenting the industrial investment in the use of exosomes in
cancer diagnostic (Sheridan, 2016). A pool of European scientists in the
ﬁeld, that networked within a COST European Project (European Net-
work on Microvesicles and Exosomes in Health and Disease: ME-
HAD), has recently published a perspective article proposing nanosized
extracellular vesicles as the future of NanoMedicine (Fais et al., 2016),
with the aim to emphasize the level of importance of EVs in the future
of Medicine as both biomarkers of disease and shuttle for therapeutic
molecules.
We know that exosomes may fuse with target cell plasma mem-
branes delivering their contents within the recipient cells (Parolini et
al., 2009), and conceivably changing their biology (Cantaluppi et al.,
2012). Thus, EVs may represent not only the future biomarkers in med-
icine (Properzi et al., 2013), but also a very valuable and effective
“nanovector” for either chemical or biological drugs, as well (Fais et
al., 2013). The horizon of the EVs involvement in our body function is
far to be deﬁned. Recently, EVs have been shown to transfer genes to
the germ line, thus probably contributing to our genome changes
(Cossetti et al., 2014), suggesting that they can well be the ideal vehicle
for gene therapy as well. In fact, the possibility of modifying their con-
tent by bioengineering methods is another important endpoint of clini-
cal scientists involved in “teranostics”, aiming at usingmolecules which
are the same time tracers and therapeutic agents (Corbin and Zheng,
2007; Dai et al., 2008; Lammers, et al., 2011; Kooijmans et al., 2012; El
Andaloussi et al., 2013b; Cooper et al., 2014; Fang et al., 2014). A scheme
for the clinical use of exosomes in the diagnostic ﬁeld is shown in the
Graphical Abstract, but we are more than convinced that the clinical
use of exosomes is probably without border (Escudier et al., 2005), or
at least this is our hope.
In conclusion, the ﬁeld of exosomology is in great expansion and the
future appears very promising. Scientiﬁc discussion among experts in
the ﬁeld are crucial to reach the goals in a near future, concentrating
in optimizing economic resources for the interest of patients. We pro-
pose the use of EVs quantiﬁcation in the body ﬂuids of cancer patients
as thedeﬁnition of “Liquid TumorMass” for the early diagnosis of cancer
and cancer relapses, aswell, andwe hopewith this perspective article to
trigger a fruitful discussion on this issue.
With this TEM pictures we want to summarize the mechanisms of
exosomes formation and secretion (Stoorvogel et al., 2002): 1) The in-
ward budding of clathrin-coatedmicro domains on the plasmaticmem-
brane; 2) The intra-lumen vesicles (ILV) formation, which bud inwards
and pinch off into the lumen of the multivesicular bodies (MVBs); 3)
The extracellular secretion of the exosomes.y ﬂuid Method Ref.
m FACS Caivano et al., 2015
e TR-FIA Duijvesz et al., 2015
ma ELISA Khan et al., 2012
ma NTA Nawaz et al., 2014
tatic secretions MALDI-TOF, HPLC, MS Nyalwidhe et al., 2013
ma Western blot Campanella et al., 2015
ma FACS Silva et al., 2012
ma ELISA Logozzi et al., 2009
m Electro-chemiluminescence Alegre et al., 2016
ma NTA Peinado et al., 2012
m NTA Melo et al., 2015
ma RT-PCR, western blot Lowry et al., 2015
ma FACS Ogorevc et al., 2013
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taining multi-vesicular bodies (MVBs) ﬁlled of vesicles of different
size, including nanovesicles, in proximity to the plasma membrane
(bar 500 nm). Panel (B) shows epon-embedded and sectioned
exosomes after secretion with the typical ultrastructural features: the
lipid bilayer and range in size from 30 to 100 nm. The picture includes
both single vesicles and clusters of vesicles (bar 200 nm). Panel (C)
shows some detail of vesicles of different size, ranging from 187 and
80 nm of diameter (bar 200 nm).
Further methodological details: extracellular vesicles were obtained
by ultracentrifugation. Brieﬂy, 50 ml of cell-free medium was collected
and centrifuged at 13,000 ×g for 20min at 4 °C to bring down and elim-
inate small cellular debris and mitochondrial contaminants. The super-
natant was collected, and exosomes were obtained by
ultracentrifugation at 110,000 ×g for 2 h at 4 °C. The pellet was collected
andwashed once in PBS, resuspended in 100 μl of PBS containing prote-
ase inhibitors, and stored at−80 °C until use (Campanella et al., 2012).
The exosomes suspension was ﬁxed with Karnovsky's ﬁxative and then
embedded for electron microscopy.
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